(MENAFN- GlobeNewsWire - Nasdaq) Growth is driven by increasing demand for personalized treatment, improved delivery technologies, and biosimilars, despite challenges like high costs and regulatory demands

Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Rapid Acting Insulin Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets's offering.
The Rapid Acting Insulin Market valued at USD 7.71 billion in 2024 is anticipated to grow strongly to USD 11.77 billion by 2033. This growth represents a strong compound annual growth rate (CAGR) of 4.81% from 2025 to 2033.

Growth Drivers for the Rapid Acting Insulin Market

Increasing Global Prevalence of Diabetes

The rising global diabetes burden, particularly Type 1 and Type 2, is a key driver for the rapid acting insulin market. As per the International Diabetes Federation, more than 530 million adults lived with diabetes in 2023, and the number is expected to increase consistently. This increase in diabetic patient populations is directly attributed to increasing demand for effective, fast-acting insulin treatments to manage postprandial blood glucose.

As more patients need accurate insulin dosing, healthcare professionals are prescribing rapid acting insulin as part of personalized treatment plans. Governments and healthcare systems are also investing more in diabetes awareness and treatment facilities, further propelling market growth. As of recent projections, more than 537 million adults have diabetes worldwide, and this number is estimated to reach 700 million by 2045.

Advances in Insulin Delivery Devices

Technological advancements in insulin pens, pumps, and continuous glucose monitoring systems have greatly improved the convenience and effectiveness of rapid acting insulin. Current delivery devices offer patients precise, easy dosing, lowering the risk of hypoglycemia and maximizing glycemic control. These developments have aided increased uptake of rapid acting insulins by younger and more technologically advanced patients, along with better adherence to treatment.

Compatibility with diabetes management apps and smart insulin pens also enhances the popularity of these insulins. With more device and pharmaceutical companies coming together, these technologies are simplifying therapy, decreasing administration errors, and improving the quality of life for patients, thereby supporting market growth. Aug 2024, Abbott and Medtronic have partnered to create an integrated continuous glucose monitoring (CGM) system based on Abbott's FreeStyle Libre technology. The system will be combined with Medtronic's automated insulin delivery and smart insulin pen systems to automatically adjust insulin doses. Abbott will design the CGM sensor and Medtronic will sell it.

Shift Toward Personalized and Intensive Insulin Therapy

The growing need for precision medicine in the management of diabetes has raised the level of importance for rapid acting insulin in individualized treatment regimens. Physicians are now concerned with intensive insulin therapy that reflects physiological insulin release closely, specifically for Type 1 diabetics and Type 2 diabetic patients who use insulin. Rapid acting insulin is a pivotal component of the strategy, regulating blood sugar excursions following food intake.

In addition, awareness of patient benefits for tighter glycemic control, such as reduced risks of long-term complications, is growing. Coupled with patient-focused treatment approaches and increased application of CGM data to direct insulin dosing, demand for rapid acting insulin is being driven globally. Nov 2024, The InsuJet Needle-free Device harnesses innovative jet injection technology to administer accurate insulin doses without the use of needles. It reduces discomfort and anxiety concerning needle injections.

Drawbacks of the Rapid Acting Insulin Market

High Cost of Rapid Acting Insulin

One of the major drawbacks in the market of rapid acting insulin is that it is too costly, especially in nations lacking widespread healthcare coverage. Insulin lispro and insulin aspart are usually priced above human insulin, making them unavailable to low- and middle-income countries' patients. Even in developed markets such as the U.S., the affordability of insulin remains a significant issue that triggers public pressure as well as policy action.

Although biosimilars are gradually coming into the market to fix the problem of price, regulatory obstacles and brand strength continue to be limiting factors. Exorbitant prices usually result in high rates of insulin rationing, lowered compliance, and undesirable health consequences, defiling market potential in underserved areas.

Regulated and Cold Chain Requirements

Manufacture, approval, and distribution of rapid acting insulin demand compliance with strict regulatory controls and temperature-controlled supply. Sustaining the cold chain during the supply chain is essential to ensuring insulin effectiveness and potency. This creates logistics issues, especially in developing countries with poor infrastructure.

The process of regulatory approval for biosimilars is complicated and takes time, delaying entry into market and competition. Companies have to spend a lot on R&D and clinical trials in order to satisfy safety and efficacy requirements. These supply and regulatory restrictions can reduce product availability, influence pricing strategies, and impede the timely launch of new or enhanced formulations in international markets.

Key Attributes

Report Attribute	Details
No. of Pages	200
Forecast Period	2024-2033
Estimated Market Value (USD) in 2024	$7.71 Billion
Forecasted Market Value (USD) by 2033	$11.77 Billion
Compound Annual Growth Rate	4.8%
Regions Covered	Global

Key Topics Covered
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities
5. Global Rapid Acting Insulin Market
6. Market Share Analysis
6.1 By Product
6.2 By Indication
6.3 By Distribution Channel
6.4 By Countries
7. Products
7.1 Lispro Insulin
7.2 Aspart Insulin
7.3 Glulisine Insulin
8. Indications
8.1 Type 1 Diabetes
8.2 Type 2 Diabetes
9. Distribution Channels
9.1 Hospital Pharmacies
9.2 Drug Stores and Retail Pharmacies
9.3 Online Stores
10. Countries
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherland
10.3 Asia-Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Thailand
10.3.7 Malaysia
10.3.8 Indonesia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 South Africa
10.5.2 Saudi Arabia
10.5.3 Turkey
10.5.4 UAE
11. Porter's Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Key Players Analysis
13.1 Adocia
13.2 Biocon Limited
13.3 Eli Lilly and Company
13.4 Gan & Lee Pharmaceuticals Co. Ltd.
13.5 Geropharm
13.6 MannKind Corporation
13.7 Merck & Co. Inc.
13.8 Novo Nordisk A/S
13.9 Sanofi SA
13.10 Wockhardt Ltd.
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Rapid Acting Insulin Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN06112025004107003653ID1110306245